Today hasn’t been the best day for United States markets. However, even during bad days, there are always opportunities for gains. I’ve been following three stocks incredibly closely over the past several months, and I think there are nice opportunities surrounding them. Here they are…
Synergy Pharmaceuticals Is Bound To Go Higher
Synergy Pharmaceuticals Inc (NASDAQ: SGYP)
Synergy Pharmaceuticals has been a stock that I’ve discussed in great detail over the past week; and for good reason. Last week, the company released data with regard to a Phase 3 study of the experimental drug plecanatide. The drug is designed to treat patients with irritable bowel syndrome with constipation (IBS-C). The results from the most recent study showed that not only was the drug effective, it resulted in less instances of diarrhea as a side effect than the current market leader, Linzess. Overall the data was overwhelmingly positive. Throughout the beginning of the week however, the stock corrected; which led to quite the opportunity as it has started to see declines again today. Keep an eye on this one as they have initiated the second of 2 phase 3 studies into plecanatide. So, we’re likely to see more good news, and more positive growth from the stock moving forward.
MannKind Stock Is Going To Grow
MannKind Corporation (NASDAQ: MNKD)
If you follow my writing either here or elsewhere, you know by now that I’m a big fan of MannKind; not just of their stock, but of their product. MannKind Afrezza is an inhaled insulin; something we’ve never seen before. However, there’s been interesting behavior around the stock because of this product. The reality is that MannKind is worth investing in, but because of a poor pre-launch, investors are waiting for the big news. As a result, MNKD is being kept low in the market. However, I don’t expect that it’s going to continue trading this low for much longer. Pretty soon, within weeks to be exact, Afrezza will be entered into the Direct-to-Consumer campaign. This campaign is going to increase sales and investors will get excited; ultimately pushing the value of MNKD very high.
Gilead Sciences Stock Presents A Very Unique Opportunity
Gilead Sciences, Inc. (NASDAQ: GILD)
Gilead Sciences is a very interesting one because it presents a unique opportunity. While we’ve seen growth in the stock, it hasn’t been at the pace it deserves. Don’t get me wrong, I understand that GILD is trading at a record high, but it could be better. For proof, just look at the stock’s P/E ratio. While most US stocks are ranging in the 16-17 range; GILD is below 10! The reason the stock is trading so cheap is simple…Investors saw the entrance of AbbVie into the HCV market as a threat to Gilead’s continued control over the space. So, while GILD earnings continued to grow, investors were hesitant to push the value of the stock up. However, I don’t think prices are going to stay low forever. The bottom line is that GILD will continue to prove that it maintains control over the HCV market; leading to increases in the value of its stock.
Do You Know Of Any Others?
Do you know of any other strong opportunities in biotech? If so, let us know in the comments below.
